LAZARD ASSET MANAGEMENT LLC
Position in PLX — Protalix BioTherapeutics, Inc.
CIK 1207017
NEW YORK, NY
Position in PLX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$385,757
+$197,799 QoQ
Shares Held
165,561
+91.1% QoQ
Ownership
0.205%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#20
of 101 holders
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026LAZARD ASSET MANAGEMENT LLC holds $400,660,289 across 59 Biotechnology names. PLX ranks #43 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
131,996 | $122,461,928 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
93,287 | $46,338,451 | |
| 3 | ONC |
BeOne Medicines Ltd.
|
90,348 | $25,746,469 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
36,910 | $23,014,861 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
350,397 | $20,049,716 | |
| 6 | EXEL |
Exelixis, Inc.
|
343,029 | $18,664,207 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
69,588 | $16,768,620 | |
| 8 | INCY |
Incyte Corp
|
136,684 | $15,494,498 |
All Filings in PLX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $385,757 | 165,561 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $187,958 | 86,617 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $128,507 | 71,393 | Shares | Sole | 2026-02-17 | |
| 2025-03-31 | $2,040 | 797 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $2 | 1,255 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||